Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with 177Lu: in vitro comparison of acyclic and macrocyclic ligands

Nuclear Medicine and Biology

Volumn 36, Issue 2, 2009, Pages 117-128

  Hens, Marc ^a   Vaidyanathan, Ganesan ^a   Welsh, Phil ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DOTA; DTPA; Epidermal growth factor receptor; Lu 177; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 (4 ISOTHIOCYANATOBENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID; [2 AMINO 3 (4 ISOTHIOCYANATOPHENYL)PROPYL]CYCLOHEXANE 1,2 DIAMINEPENTAACETIC ACID; ACETIC ACID DERIVATIVE; ALPHA (5 ISOTHIOCYANATO 2 METHOXYPHENYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; IODINE 125; LUTETIUM 177; MACROCYCLIC COMPOUND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L8A4; N SUCCINIMIDYL 4 GUANIDINOMETHYL 3 IODOBENZOATE I 125; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ARTICLE; BRAIN TUMOR; CELL LABELING; CHELATION; GLIOMA CELL; HUMAN; IN VITRO STUDY; INTERNALIZATION; INTRACELLULAR TRANSPORT; LIGAND BINDING; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; RADIOIODINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLIOMA; ISOTOPE LABELING; LIGANDS; LUTETIUM; MACROCYCLIC COMPOUNDS; MICE; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 59649083434     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.11.001     Document Type: Article

References (45)

1. Garcia de Palazzo I.E., Adams G.P., Sundareshan P., Wong A.J., Testa J.R., Bigner D.D., and Weiner L.M. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53 (1993) 3217-3220
2. Schwechheimer K., Huang S., and Cavenee W.K. EGFR Gene amplification-rearrangement in human glioblastomas. Int J Cancer 62 (1995) 145-148
3. Antonyak M.A., Moscatello D.K., and Wong A.J. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 273 (1998) 2817-2822
4. Moscatello D.K., Holgado-Madruga M., Emlet D.R., et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273 (1998) 200-206
5. Wikstrand C.J., Reist C.J., Archer G.E., Zalutsky M.R., and Bigner D.D. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J NeuroVirol 4 (1998) 148-158
6. O'Donoghue J.A., Bsrdies M., and Wheldon T.E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36 (1995) 1902-1909
7. Reardon D.A., Zalutsky M.R., and Bigner D.D. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anti-Cancer Therapy 7 (2007) 675-687
8. DeNardo G.L., DeNardo S.J., and Miyao N.P. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies. Int J Biol Markers 3 (1988) 1-9
9. Hanna R., Ong G.L., and Mattes M.J. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res 56 (1996) 3062-3068
10. Heeg M.J., and Jurisson S.S. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc Chem Res 32 (1999) 1053-1060
11. Press O.W., Shan D., Howell-Clark J., Eary J., Appelbaum F.R., Matthews D., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56 (1996) 2123-2129
12. Shih L.B., Thorpe S.R., Griffiths G.L., Diril H., Ong G.L., Hansen H.J., et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 35 (1994) 899-908
13. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
14. Volkert W.A., Goeckler W.F., Ehrhardt G.J., and Ketring A.R. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med 32 (1991) 174-185
15. Ahlgren S., Orlova A., Rosik D., Sandström M., Sjöberg A., Baastrup B., et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjugate Chem 19 (2008) 235-243
16. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl Med Biol 31 (2004) 753-759
17. 64Cu-labeled DOTA-linker-bombesin (7-14) analogues containing different amino acid linker moieties. Bioconjugate Chem 18 (2007) 1110-1117
18. Smith-Jones P.M., Vallabahajosula S., Goldsmith S.J., Navarro V., Hunter C.J., Bastidas D., et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60 (2000) 5237-5243
19. Bousquet J.C., Saini S., Stark D.D., Hahn P.F., Nigam M., Wittenberg J., et al. Gd-DOTA: characterization of a new paramagnetic complex. Radiology 166 (1988) 693-698
20. McMurry T.J., Brechbiel M., Kumar K., and Gansow O.A. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjugate Chem 3 (1992) 108-117
21. Moi M.K., Meares C.F., and DeNardo S.J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid and study of its yttrium(III) complex. Journal of the American Chemical Society 110 (1988) 6266-6267
22. Parker D. Tumour targeting with radiolabelled macrocycle-antibody conjugates. Chem Soc Rev 19 (1990) 271-291
23. Woods M., Kovacs Z., Kiraly R., Brucher E., Zhang S., and Sherry A.D. Solution dynamics and stability of lanthanide(III) (S)-2-(p-nitrobenzyl)-DOTA complexes. Inorg Chem (2004) 2845-2851
24. Durbin P. Metabolic characteristics within a chemical family. Health Phys 2 (1960) 225-228
25. 177Lu, or 186Re. J Nucl Med 45 (2003) 327-337
26. 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 32 (2005) 264-273
27. 64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res 11 (2005) 5112-5120
28. 88Y-labeled hLL2 (epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm 18 (2003) 525-533
29. 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47 (2006) 1127-1135
30. 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nuclear Medicine and Biology 34 (2007) 173-183
31. 131I]SGMIB). Bioconjugate Chem 12 (2001) 428-438
32. Humphrey P.A., Wong A.J., Vogelstein B., Zalutsky M.R., Fuller G.N., Archer G.E., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Nat Acad Sci U S A 87 (1990) 4207-4211
33. Wikstrand C.J., Hale L.P., Batra S.K., Hill L., Humphrey P.A., Kurpad S.K., et al. Monoclonal antibodies against EGFRvllI are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55 (1995) 3140-3148
34. Stetter H., and Frank W. Complex formation with tetraazacycloalkane-N,N′,N″,N′″-tetraacetic acids as a function of ring size. Angewandte Chemie 88 (1976) 760
35. Pippin C.G., Parker T., McMurry T.J., and Brechbiel M.W. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjugate Chemistry 3 (1992) 342-344
36. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29 (2002) 431-442
37. Foulon C.F., Reist C.J., Bigner D.D., and Zalutsky M.R. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 60 (2000) 4453-4460
38. Lindmo T., Boven E., Cuttitta F., Fedorko J., and Bunn Jr. P.A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72 (1984) 77-89
39. Reist C.J., Archer G.E., Kurpad S.N., Wikstrand C.J., Vaidyanathan G., Willingham M.C., et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55 (1995) 4375-4382
40. Enam S.A., Rosenblum M.L., and Edvardsen K. Role of extracellular matrix in tumor invasion: migration of glioma cells along fibronectin-positive mesenchymal cell processes. Neurosurgery 42 (1998) 599-607
41. 131I]iodo-4-phosphonomethylbenzoate, a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjugate Chem 14 (2003) 331-341
42. *I]IB-Mal-d-GEEEK): a radioiodinated prosthetic group containing negatively charged d-glutamates for labeling internalizing monoclonal antibodies. Bioconjugate Chem 17 (2006) 1085-1092
43. Anderson C.J., and Welch M. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 99 (1999) 2219-2234
44. 111In-DTPA-epsilon-lysine as the primary metabolic and excretory product. Nucl Med Biol 21 (1994) 1023-1034
45. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res 55 Suppl (1995) 5714s-5720s